Fig. 6

ILF2 promoted TNBC progression by regulating the transcription of IDH2. A Correlation analysis between IDH2 and HNRNPK expression in BRCA s and normals using TCGA dataset at GEPIA. B Correlation analysis between IDH2 and ILF2 expression in BRCA tumors and normals using TCGA dataset at GEPIA. C qRT-PCR assay revealed the expression level of IDH2 in TNBC cells with HNRNPK knockdown (left) or HNRNPK overexpression (right). D Immunoblot analysis displayed the levels of IDH2, HNRNPK, and ILF2 in TNBC cells with HNRNPK knockdown (left) or HNRNPK overexpression (right), using GAPDH as a loading control. E qRT-PCR assay showcased the expression level of IDH2 in TNBC cells with ILF2 knockdown (left) or ILF2 overexpression (right). F Immunoblot analysis depicted the levels of IDH2 and ILF2 in TNBC cells with ILF2 knockdown (left) or ILF2 overexpression (right), with GAPDH as a loading control. G Immunoblot analysis displayed the levels of IDH2 in MDA-MB-231 cells co-transfected with shHNRNPK and ILF2 (left). qRT-PCR assay illustrated the expression level of IDH2 in MDA-MB-231 cells co-transfected with shHNRNPK and ILF2 (right). H Immunoblot analysis showed the levels of IDH2 in BT-549 cells co-transfected with HNRNPK and shILF2 (left). qRT-PCR assay revealed the expression level of IDH2 in BT-549 cells co-transfected with HNRNPK and shILF2 (right). I-J Impact of ILF2 overexpression (I) or knockdown (J) on luciferase activity in the IDH2 promoter region. Statistical analyses are depicted in bar graphs. Data are presented as mean ± SD from three independent experiments. Significance levels are denoted as * for p<0.05, ** for p<0.01, and *** for p<0.001, as determined by the t-test